Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna(R) Compared to Gleevec(R) - Drugs.com MedNews
Links shared publicly online about this topic.
- 0total visits
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna(R) Compared to Gleevec(R) - Drugs.com MedNews
- ENESTcmr data show 23 of patients switched to Tasigna achieved undetectable levels of Bcr-Abl within 12 months compared to 11 who continued on Gleevec(1) - Th
View full resource at drugs.com
Tags: Leukemia, Chronic Myelogenous Leukemia, Drug, Novartis
Most Recently Shared on December 13, 2011 at 9:08 pm By:
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With ... http://t.co/bjIGsVlC #drug
Advertisement
